140 related articles for article (PubMed ID: 8624465)
1. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease.
Fleury J; Legros M; Colombat P; Cure H; Travade P; Tortochaux J; Dionet C; Chollet P; Linassier C; Lamagnere JP; Blaise D; Viens P; Maraninchi D; Plagne R
Leuk Lymphoma; 1996 Jan; 20(3-4):259-66. PubMed ID: 8624465
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.
Nademanee A; Molina A; Fung H; Stein A; Parker P; Planas I; O'Donnell MR; Snyder DS; Kashyap A; Spielberger R; Bhatia R; Krishnan A; Sniecinski I; Vora N; Slovak M; Dagis A; Niland JC; Forman SJ
Biol Blood Marrow Transplant; 1999; 5(5):292-8. PubMed ID: 10534059
[TBL] [Abstract][Full Text] [Related]
3. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.
Carella Am; Carlier P; Congiu A; Occhini D; Meloni G; Anselmo AP; Mandelli F; Mazza P; Tura S; Mangoni L
Leukemia; 1991; 5 Suppl 1():68-71. PubMed ID: 1890870
[TBL] [Abstract][Full Text] [Related]
4. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival.
Poen JC; Hoppe RT; Horning SJ
Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):3-12. PubMed ID: 8823253
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
Carella AM; Carlier P; Congiu A; Occhini D; Nati S; Santini G; Pierluigi D; Giordano D; Bacigalupo A; Damasio E
Bone Marrow Transplant; 1991 Aug; 8(2):99-103. PubMed ID: 1718517
[TBL] [Abstract][Full Text] [Related]
10. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
[TBL] [Abstract][Full Text] [Related]
11. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma.
Prince HM; Crump M; Imrie K; Stewart AK; Girouard C; Brandwein JM; Carstairs K; Pantalony D; Scott G; Sutcliffe S; Sutton DM; Tsang R; Keating A
Ann Oncol; 1996 Dec; 7(10):1043-9. PubMed ID: 9037363
[TBL] [Abstract][Full Text] [Related]
12. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM
J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717
[TBL] [Abstract][Full Text] [Related]
15. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
16. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
O'Brien ME; Milan S; Cunningham D; Jones AL; Nicolson M; Selby P; Hickish T; Hill M; Gore ME; Viner C
Br J Cancer; 1996 May; 73(10):1272-7. PubMed ID: 8630292
[TBL] [Abstract][Full Text] [Related]
18. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
Da WM; Zhong JT; Liu Y; Huang YS; Bai H; Wu XX; Ou YX; Wang CB; Xu SF
Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]